Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2520897 | 0.91 | TSHR (0.63) | TSHRRECQLGAAKMT2AMEN1 | |
| SCHEMBL8533502 | 0.89 | TSHR (0.69) | TSHRRECQLGAAKMT2AMEN1 | |
| SCHEMBL17550886 | 0.79 | GAA (0.72) | TSHRRECQLGAAKMT2AMEN1 | |
| SCHEMBL12292116 | 0.79 | TSHR (0.65) | TSHRRECQLGAAKMT2AMEN1 | |
| SCHEMBL15850415 | 0.79 | TSHR (0.69) | TSHRRECQLGAAKMT2AMEN1 | |
| SCHEMBL26576519 | 0.77 | EPHX2 (0.61) | TSHRRECQLGAAKMT2AMEN1 | |
| SCHEMBL8464732 | 0.77 | MEN1 (0.76) | TSHRRECQLGAAKMT2AMEN1 | |
| SCHEMBL26576518 | 0.77 | EPHX2 (0.61) | TSHRRECQLGAAKMT2AMEN1 | |
| SCHEMBL14544164 | 0.76 | GAA (0.72) | TSHRRECQLGAAKMT2AMEN1 | |
| SCHEMBL770934 | 0.76 | CYP3A4 (0.87) | TSHRRECQLGAAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9108902-B2 | Deuterated 2-amino-3-hydroxypropanoic acid derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20140221492-A1 | DEUTERATED 2-AMINO-3-HYDROXYPROPANOIC ACID DERIVATIVES | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221492-A1 | DEUTERATED 2-AMINO-3-HYDROXYPROPANOIC ACID DERIVATIVES | GRIN3A, GRIK5, GRIN2A | TSHR 4060/4885RECQL 4542/4885GAA 3252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.